Metra Biosystems expecting to net $30.1 mil. in IPO.
This article was originally published in The Gray Sheet
Executive Summary
METRA BIOSYSTEMS' PYRILINKS(II) AND PYRILINKS-D 510(K)s were submitted on May 30 and May 17, respectively, giving the firm three pending 510(k)s for bone resorption assays. According to a recent filing with the Securities and Exchange Commission for an initial public offering, the Mountain View, California-based firm submitted a reworked 510(k) in April for its first bone resorption immunoassay, Pyrilinks, and plans to submit in early June a 510(k) for a fourth product, the Alkaphase-B bone formation assay.